GDTC - CytoMed Therapeutics Sotuvga nisbatan narx

CytoMed (GDTC) kompaniyasining korporativ logotipi

CytoMed Therapeutics (GDTC) hozirda savdo tushruklari yo'qligi sababli klinik bosqichlarni moliyalashtirish uchun to'plangan kapitalidan foydalanmoqda. Universal dozalarni joriy etish orqali samaradorlikni oshirish mumkin, bu esa murakkab biomanufakturingni soddalashtiradi. Fundamental P/S ko'rsatkichi joriy aktivlar bahosini tasdiqlaydi, bunda 39.90 belgisi eng so'nggi ma'lumotlarni aks ettiradi. Bu donor hujayralaridan olingan hamyonbop CAR-T va CAR-NK terapiyalarini yaratish yo'nalishini qo'llab-quvvatlaydi.

GDTC - CytoMed Therapeutics Narxning daromadga nisbati 01.05.2025 - 13.11.2026 oraligʻida

CytoMed Therapeutics (GDTC) kompaniyasining tahliliy kesimlari

- bozor narxi va tahlilchilarning maqsadli narxlari:
Aksiya kotirovkalari w2.cytomed.sg|GDTC - Konsensus maqsadli narx
- bozor kapitallashuvi statistikasi:
Bozor qiymati CytoMed|GDTC - Kompaniyani butunlay sotib olishdagi haqiqiy narx
- aksiyadorlik kapitalining balans qiymati ma'lumotlari:
Aksiyaning balans narxi CytoMed Therapeutics|GDTC - Kompaniyaning balans qiymati|Bozor qiymatining balans qiymatiga koeffitsiyenti w2.cytomed.sg|GDTC - Kompaniyaning jami aktivlari
- biznesning qarz tarkibi va likvidligi tafsilotlari:
Umumiy qarzning xususiy kapitalga nisbati CytoMed Therapeutics|GDTC - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli majburiyatlarning kapitalga nisbati w2.cytomed.sg|GDTC - Kompaniyaning jamlangan qarzlari|Qarzning balans qiymatiga nisbati CytoMed|GDTC - Kompaniyaning uzoq muddatli majburiyatlari|Kompaniyaning qisqa muddatli kredit va qarzlari CytoMed Therapeutics|Oraliq likvidlik koeffitsiyenti w2.cytomed.sg
- foyda va bozor koeffitsiyentlari statistikasi:
GDTC - Sof foyda|Kutilayotgan sof daromad CytoMed Therapeutics|GDTC - P/E multiplikatori|Prognoz qilingan narx-foyda nisbati w2.cytomed.sg|GDTC - Narxning foydaga va o‘sish sur’atiga nisbati|Biznes qiymatining amortizatsiya chegirilishidan oldingi operatsion foydaga nisbati CytoMed|GDTC - EBITDA operatsion foydasi|Bir aksiya uchun sof foyda (EPS TTM) CytoMed Therapeutics|GDTC - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi o'n ikki oy davomida bir aksiya uchun sof foydaning yillik dinamikasi w2.cytomed.sg|GDTC - Joriy yilda foyda o'sishi|Keyingi yilda bir aksiya uchun sof foydaning kutilayotgan o'sishi CytoMed Therapeutics
- umumiy tushum va sotuv hajmi ma'lumotlari:
GDTC - Kompaniya savdosi|Prognoz qilingan sotish hajmi w2.cytomed.sg|GDTC - Kapitalizatsiyaning daromadga nisbati|Narxning kutilayotgan daromadga nisbati CytoMed
Kompaniyaning umumiy tahlili:CytoMed Therapeutics Ltd (GDTC)
CytoMed original mahsuloti

CytoMed Therapeutics (GDTC) onkologik hujayra terapiyasi segmentida intensiv ishlanmalarni olib bormoqda va kapitalga boy biotexnologiya gigantlari bilan raqobatlashmoqda. P/S koeffitsiyenti biznesning bozor qiymatini uning generatsiya qilgan daromadlari bilan solishtirib, aktivning haddan tashqari qimmat baholanganlik darajasini aniqlaydi. Investorlar bozor beqarorligi davrida kapitalning xavfsiz boshpana chegarasini baholash uchun ushbu koeffitsiyentdan foydalanadilar. Sotuvga nisbatan narx koeffitsiyenti o'zgarishlarini tahlil qilish orqali emissiyaning aksiyalarini yashirin taqsimlash yoki stagnatsiya bosqichlarini aniqlash mumkin.

CytoMed Therapeutics kimlar bilan raqobatlashadi

Kapitalizatsiyaning daromadga nisbati beigene.com ONC|Halozyme - Kapitalizatsiyaning daromadga nisbati|Revolution Medicines Inc (RVMD) - Sotuvga nisbatan narx|AAPG: Kapitalizatsiyaning daromadga nisbati|CG Oncology Therapeutics - Kapitalizatsiyaning sotish hajmiga nisbati|UroGen Pharma Ltd. (URGN) - Narxning daromadga nisbati|Sotuvga nisbatan narx bicara.com (BCAX)|Narxning daromadga nisbati Personalis|Kapitalizatsiyaning daromadga nisbati Erasca Inc (ERAS)|P/S multiplikatori DCTH|YMAB - Sotuvga nisbatan narx|P/S multiplikatori AURA (Aura Biosciences, Inc.)|CADL: Kapitalizatsiya va daromad nisbati|ARAY: Kapitalizatsiyaning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati SLS (SELLAS Life Sciences)|ACTU (Actuate Therapeutics, Inc) - Kapitalizatsiyaning daromadga nisbati|CTOR: Kapitalizatsiyaning sotish hajmiga nisbati|HURA (TuHURA Biosciences Inc.) - P/S multiplikatori|TARA: Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori FATE|WHWK - Sotuvga nisbatan narx|Narxning daromadga nisbati TScan Therapeutics, Inc. TCRX|Bozor kapitallashuvining daromadga nisbati CSBR|XBiotech USA - P/S multiplikatori|CVM - P/S multiplikatori|OS Therapies (OSTX) - Narxning daromadga nisbati|Narxning sotuvga nisbati RADX (radiopharmtheranostics.com)|ARTV (Artiva Biotherapeutics Inc.) - P/S multiplikatori|Sotuvga nisbatan narx Adlai Nortye Limited ANL|Kapitalizatsiyaning daromadga nisbati VERU (Veru Inc.)|P/S multiplikatori tempesttx.com (TPST)|Xilio Therapeutics - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiyaning sotish hajmiga nisbati RENB (Renovaro Biosciences)|Mural Bio - P/S multiplikatori|Narx/daromad koeffitsiyenti Kairos Pharma Ltd KAPA|OKUR: P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati Curis|Narxning daromadga nisbati Apollomics Inc.|Tharimmune Inc (THAR) - Narx/daromad koeffitsiyenti|P/S multiplikatori ADVB|Genprex Inc (GNPX) - Narx/daromad multiplikatori|P/S multiplikatori CLDI (Calidi Biotherapeutics, Inc.)|SBFM: Kapitalizatsiya va daromad nisbati|XBIO: Kapitalizatsiyaning daromadga nisbati|Salarius Pharmaceuticals Inc - Kapitalizatsiyaning sotish hajmiga nisbati|PPBT: P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati American Oncology Network, Inc.|BGNE (BeiGene, Ltd.) - P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati checkpointtx.com (CKPT)|P/S multiplikatori ELEV|P/S multiplikatori icadmed.com (ICAD)|Narxning daromadga nisbati Ikena Oncology IKNA|NTBL: Kapitalizatsiya va daromad nisbati|Viracta - P/S multiplikatori|morphosys.com (MOR) - Kapitalizatsiyaning daromadga nisbati|NAYA: P/S multiplikatori|Sotuvga nisbatan narx Ascentage Pharma Group International (AAPGV)